The MOPEAD consortium has proposed a programme of work carefully aligned to the objectives of IMI2 Call to deliver a step-change in AD-related patient engagement (PE) strategies and a paradigm shift in early stage care. It aims to improve patient engagement in three categories: 1) Pre-clinical AD (the most important for prevention trials; 2) Prodromal AD (i.e. MCI with positive amyloid biomarkers); and 3) Very Mild AD. MOPEAD offers four different and complementary strategies, namely AD Citizen-Science, Open House Initiative (OHI), Primary Care Campaign (PCC), and Type 2 Diabetes (T2DM). It seeks subjects eligible for CT scan in all three mentioned categories. The central concept is to test and evaluate the four Patient Engagement models (Runs) to help identify patients at risk of AD in a five-country, multi-centre setting. It builds upon an already successful model, the Open House Initiative pioneered by the coordinator (FACE). Five countries (ES, DE, NL, SE and SL) have been selected to implement these models based upon relevant expertise; the consortium brings together partners for their potential to become long-term assets to European efforts to tackle AD challenges. The methodology involves enhanced pre-screening protocols to select individuals for conventional screening associated to an RCT. Eligible subjects will be invited to formal evaluation using a protocol consensus with EPFIA. MOPEAD possesses confident baseline metrics from which to measure progress and determine the efficacy of PE strategies compared to primary care. Although baseline data exists for only three of the four proposed models, the new model AD Citizen Science approach will add significantly to the holistic approach of the project. The proposal addresses the specific cross-border challenge of improving health care and reducing the economic burden related to AD by means of identifying those patients at risk of developing AD. This will cover a significant gap in the healthcare system.

ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and lactation. What do we deliver? ConcePTION aims to create a paradigm shift in how we study medication safety in pregnancy. We will establish (1) a successful, sustainable open-science based EU non-proprietary ecosystem of public and private stakeholders, pregnant women and researchers to generate and disseminate timely and reliable evidence on drugs across maternal, neonatal and long term outcomes of medication exposure in pregnancy and breastfeeding (2) a catalogue with fully characterized data sources for rapid selection of suitable data sources; 3) operational, business, network, information and data governance models, (4) quality assured and tested methodological approaches, analytical tools and data platforms allowing for distributed analyses, (5) procedures and tools for collection of digital data and samples directly from pregnant women, (6) In vitro, in silico and in vivo models for prediction of drug transfer in human milk, (7) a biobank and analytical network for quantification of drug in human milk, (8) best practice documents endorsed by regulators and health authorities and (9) a web-based drug information knowledge bank. How do we deliver? (1) Experienced leaders, able to manage challenging networks and public-public or public-private partnerships. (2) Defragmentation by connecting all key stakeholders and EU networks in this area. (3) Re-use of data, tools and foreground from prior European commission funded projects. (4) Connecting to leaders of similar initiatives in the USA, Canada, Asia and other parts of the world. (5) Systematic consensus & endorsement building. (6) Quality throughout as a precondition to trust the results and information by all users.

GoNano has as its main objective to improve the responsiveness of research & innovation processes to public values and concerns. The project builds on previous projects in public engagement and new technologies to develop a pilot project in each of the nanotechnology research areas ‘Health’, ‘Energy’ and ‘Food’. The pilot projects will engage citizens with researchers, professional users, civil society organisations, industry, and policy makers in a continuous process of deliberative workshops and online consultations to co-create concrete suggestions for future nanotechnologies. GoNano will build a broad community of ‘change agents’ for integrating an ‘RRI way’ of working on research and innovation, and it will develop and disseminate an RRI business case to align public values, needs and concerns with industry’ for profit ambition. GoNano builds on the basic assumption that several types of knowledge are needed to define sustainability, acceptability, and desirability of nanotechnologies, as well as the belief that online and offline engagement activities must be combined with a creative approach to dissemination and communication to ensure continued interest and engagement in the debate on nanotechnologies future application. GoNano believes that its interactive and open approach to: developing the nanotechnology product suggestion; writing policy recommendation and building an RRI business case; informing and educating about nanotechnology as well as the value of co-creation will build trust and mutual understanding among all the stakeholders, including public and private stakeholders and citizens.

Cervical cancer is the third most prevalent gynaecological cancer, after uterine body and ovarian cancers. Occurring in young women, with a peak of incidence around age 40 and death at 55 years, this cancer is one of the most marked by social inequalities. The women of the most disadvantaged social categories are those who combine both the most risk factors and poorer adherence to preventive measures that rely on vaccination against human papilloma viruses (HPV) and screening for early stage cervical lesions, starting at the age of 25 years. As almost every case of cervical cancer could be prevented by cervical screening and HPV vaccination. The different European countries have implemented cervical cancer screening practices, more or less systematic, and more or less effective, with rates of regular screening widely varying. Even in countries where this rate is high, such as Finland or Sweden, some women who are truly refractory to screening. This is a major health issue because these women are often at high-risk with a 5-year survival closely correlated with the stage of disease when discovered. The costs also increase exponentially depending on the cancer stage. Numerous randomized trials conducted around the world have attempted to improve the response rate in underscreened women. But unfortunately the response rate barely reaches 20% of these women. Many factors can explain the difficulties in obtaining a satisfactory screening rate, whether geographic distance, economic constraints, disengagement of general practitioners, education level or socioeconomic status. It is therefore a European public health problem for which we assembled a network of experts from 10 European countries (Belgium, Bulgaria, France, Germany, Ireland, Italy, Portugal, Romania, Spain, and Sweden), three research groups, the International Agency for Research on Cancer (IARC), the European Cervical Cancer Association (ECCA) and the Poverty Action Laboratory (J-PAL), and a representative association of patients, The European Institute of Women's Health (EIWH). These experts, clinicians and researchers, have expertise in screening for cancer, especially cervical cancers, in conducting large randomized clinical trials, in qualitative and quantitative analysis of social and cultural determinants, in analysis of social disparities and discrimination for access to care, or in modelling health policies. If all group members do not all have worked together in the past, numerous collaborations already took place within the group. The goal of our network is to file a research project for the H2020 SC1-PM-10-2017 call for proposal entitled “Comparing the effectiveness of existing healthcare interventions in the adult population.” This project aims to test, in partner countries, interventions to increase adherence to screening in underscreened women, with special attention, but not exclusively, to women of low socio-economic status; to evaluate the quality, and assess its drivers, of downstream management of abnormal screening findings; model interventions in different countries; to analyse the cost-effectiveness of the intervention; and finally to develop an implementation research to define the best strategy through European countries of different socioeconomic structures and disease prevalence levels. The project will be managed by a French coordinator and a steering committee of clinical researchers, and will be promoted and coordinated by the INSERM. The MRSEI funding will be used to strengthen interactions within the group, validate pillars of the program (work packages) and within these pillars refine more specifically questions deserving to be assessed.